Skip to content
November 29, 2016

Onxeo Strengthens AsiDNA Patent Protection in Europe

29 NOV, 2016
  • Composition of matter patent to be granted in Europe covering AsiDNATM and more precisely the part related to its DNA sequence until 2027
  • Any product including this specific DNA sequence will be within the scope of this patent
  • AsiDNATM’s intellectual property will now be protected by 8 complementary patent families worldwide 

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced having received communication from the European Patent Office (EPO) informing its intention to grant a new patent covering especially the particular nucleic acid molecule comprised within AsiDNATM, Onxeo’s first-in-class signal-interfering (siDNA) product candidate in the European countries.

“With the addition of this patent, AsiDNATM’s patent family will include 8 complementary patents worldwide, increasing the drugs patent protection further. The grant is another step in bringing AsiDNATM to the patients in need and we look forward to initiating the Phase I study, which is planned for 2017,” said Judith Greciet, CEO of Onxeo.

This new patent will considerably strengthen the industrial property around AsiDNATM, by protecting the particular double-stranded DNA molecule of the drug. By covering any products conjugated or including said DNA molecule, this new patent protects AsiDNATM as such but also derivatives thereof sharing the same DNA sequence.

The IP estate related to AsiDNATM consists of eight worldwide patent families, covering its technology platform, its products conjugated or not, and their therapeutic utilization as a monotherapy or in combination with radiotherapy, hyperthermia or chemotherapy as well as their method of administration and the potential biomarkers predicting the response to a therapy with AsiDNATM and/or other related products offering a protection on the product AsiDNATM as such until 2031.

Source: Onxeo